Published in Blood on May 29, 2007
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem (2008) 1.74
Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol (2011) 1.66
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis (2007) 1.27
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol (2010) 1.21
Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One (2009) 1.21
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem (2009) 1.18
Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One (2008) 1.14
Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia (2007) 1.12
Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol (2010) 1.10
Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer (2012) 1.06
Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2009) 1.02
Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med (2011) 1.02
Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair (2010) 1.02
Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells. J Biol Chem (2009) 1.01
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol (2009) 1.00
Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res (2011) 1.00
Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia (2011) 0.99
A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. Anal Chem (2011) 0.97
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget (2016) 0.96
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A (2009) 0.96
Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol (2013) 0.93
Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications. Rambam Maimonides Med J (2011) 0.92
Glycosaminoglycans in Human and Bovine Serum: Detection of Twenty-Four Heparan Sulfate and Chondroitin Sulfate Motifs Including a Novel Sialic Acid-modified Chondroitin Sulfate Linkage Hexasaccharide. Glycobiol Insights (2010) 0.90
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol (2011) 0.90
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia (2011) 0.87
Chemical synthesis of a heparan sulfate glycopeptide: syndecan-1. Angew Chem Int Ed Engl (2012) 0.83
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone (2013) 0.83
Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci (2016) 0.82
Method development and analysis of free HS and HS in proteoglycans from pre- and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes. Anal Chem (2013) 0.81
Prognostic value of heparanase expression and cellular localization in oral cancer. Head Neck (2010) 0.81
Clinical Glycomics Employing Graphitized Carbon Liquid Chromatography-Mass Spectrometry. Chromatographia (2014) 0.80
Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro. Biochem Biophys Res Commun (2010) 0.80
The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol (2013) 0.79
A cytoplasmic C-terminal fragment of Syndecan-1 is generated by sequential proteolysis and antagonizes Syndecan-1 dependent lung tumor cell migration. Oncotarget (2015) 0.78
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx. PLoS One (2010) 0.76
[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther (2015) 0.76
Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth. Cancer Res (2016) 0.76
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med (2002) 3.12
QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol (2003) 2.88
Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology (2003) 2.84
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol (1996) 2.21
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest (2001) 2.18
Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell (2006) 2.16
The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol (2004) 1.91
Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem (2003) 1.83
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest (2005) 1.77
QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci U S A (2004) 1.71
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica (2002) 1.69
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem (2005) 1.66
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem (2005) 1.64
Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood (2000) 1.54
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood (2000) 1.52
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood (2002) 1.50
Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A (2002) 1.49
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest (1998) 1.46
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem (2006) 1.41
Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J Cell Sci (2006) 1.39
Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood (2004) 1.38
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood (1993) 1.34
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 1.31
Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol (2001) 1.31
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone (2005) 1.28
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene (2006) 1.21
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood (2002) 1.19
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol (2005) 1.18
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol (1997) 1.17
Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans. Curr Drug Targets (2005) 1.14
The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol (1998) 1.11
The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans (2006) 1.11
Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev (2004) 1.10
Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res (2006) 1.07
Multiple heparan sulfate chains are required for optimal syndecan-1 function. J Biol Chem (1998) 1.05
Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle (2007) 0.96
Histidine 295 and histidine 510 are crucial for the enzymatic degradation of heparan sulfate by heparinase III. Biochemistry (2000) 0.91
Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review). Int J Oncol (2005) 0.85
Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells. Int J Cancer (1999) 0.83
Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells. Cancer Immunol Immunother (2001) 0.82
SCID-hu mice for the study of human cancer metastasis. Cancer Chemother Pharmacol (1999) 0.78
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
The molecular classification of multiple myeloma. Blood (2006) 8.77
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med (2008) 7.05
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 4.97
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol (2008) 4.37
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science (2009) 3.88
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer (2002) 3.36
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med (2008) 3.16
Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. Proc Natl Acad Sci U S A (2008) 2.77
Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol (2005) 2.67
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology (2011) 2.28
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology (2007) 2.22
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des (2007) 2.14
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis (2010) 2.10
Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics (2008) 2.09
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods (2005) 2.06